149 related articles for article (PubMed ID: 15330217)
1. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.
Miyake H; Hara I; Eto H
Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217
[TBL] [Abstract][Full Text] [Related]
2. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression.
Muramaki M; Miyake H; Yamada Y; Hara I
Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065
[TBL] [Abstract][Full Text] [Related]
4. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension.
Miyake H; Muramaki M; Furukawa J; Kurahashi T; Fujisawa M
Urology; 2010 Feb; 75(2):454-9. PubMed ID: 19854485
[TBL] [Abstract][Full Text] [Related]
5. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
6. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I
Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195
[TBL] [Abstract][Full Text] [Related]
7. [Proteases and prostatic disease: cytosolic cathepsin D].
Gómez Díaz ME; Ruibal-Morell A; Abascal García R
Arch Esp Urol; 2001 Mar; 54(2):101-7. PubMed ID: 11341113
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
9. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Kehinde EO; Maghrebi MA; Anim JT
Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
[TBL] [Abstract][Full Text] [Related]
10. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
[TBL] [Abstract][Full Text] [Related]
13. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
14. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
15. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
16. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
17. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
[TBL] [Abstract][Full Text] [Related]
18. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
[TBL] [Abstract][Full Text] [Related]
19. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
20. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
